Health Catalyst (HCAT) Losses Swell To US$178 Million Challenging Margin Improvement Narrative

Health Catalyst (HCAT) just wrapped up FY 2025 with Q4 total revenue of US$74.7 million and a basic EPS loss of US$1.28, alongside a full year trailing twelve month revenue base of US$311.1 million and a net loss of US$178.0 million. Over recent quarters the company has seen quarterly revenue move from US$79.4 million in Q1 2025 to US$80.7 million in Q2, US$76.3 million in Q3 and US$74.7 million in Q4. Basic EPS losses ranged from US$0.35 to US$1.28 per share, underscoring a business that is still absorbing heavy costs relative to its top line. For investors, the latest print keeps the focus firmly on how quickly margins can tighten and whether the current loss profile can be brought under control.

See our full analysis for Health Catalyst.

With the headline figures on the table, the next step is to set these results against the widely held narratives around Health Catalyst and see which stories about growth potential, profitability and execution hold up to the numbers.

See what the community is saying about Health Catalyst

Losses balloon to US$178 million over the year

• On a trailing twelve month basis, Health Catalyst recorded a net loss of US$177.9 million on US$311.1 million of revenue, with basic EPS at a loss of US$2.55 per share.
• Bears point out that this scale of loss, together with forecasts that HCAT is not expected to reach profitability within the next three years, lines up with concerns about long running pressure on the business model.
  • Trailing net losses have widened from US$69.5 million at FY 2024 Q4 to US$178.0 million by FY 2025 Q4, even as trailing revenue stayed in a tight band around US$300 million.
  • Critics highlight that analysts expect revenue to decline about 0.4% to 1.4% per year over the next three years while the company remains loss making, so there is no forecasted earnings inflection in the supplied data to offset current losses.

Health Catalyst Future Earnings Per Share Growth looks very different depending on whose scenario you lean toward, and skeptics warn that the current earnings trend gives their cautious view plenty of support. 🐻 Health Catalyst Bear Case

Revenue holding near US$311 million despite mixed quarters

• Across the last six quarters, quarterly revenue has moved in a relatively narrow range between US$74.7 million and US$80.7 million, feeding into trailing twelve month revenue of US$311.1 million at FY 2025 Q4.
• Analysts' consensus narrative sees this steady revenue base as a platform for margin improvement, but the data also reflect pressures that limit growth and create tension with that view.
  • Consensus assumes revenue will decline about 0.4% per year over the next three years, which contrasts with the idea of sustained revenue gains even as the company focuses on higher margin applications and cost restructuring.
  • At the same time, the consensus narrative points to US$40 million in planned annual profitability improvements, so investors are weighing a fairly flat to slightly declining top line against efforts to improve the quality of each revenue dollar.

Low 0.3x P/S multiple versus ongoing losses

• HCAT is trading around a 0.3x P/S multiple, which is well below the US Healthcare Services industry at 2.1x and below its peer group at 0.7x, according to the supplied risk and reward data.
• Bullish investors argue that this discount could be interesting if margin expansion plays out, but the earnings track record means the optimistic story has to work hard against the numbers.
  • Over the last year, the company remained unprofitable on trailing metrics, with basic EPS at a loss of US$2.55 per share and net losses of about US$178.0 million, even though losses have reportedly shrunk at an average rate of 6.8% per year over five years.
  • Supporters point to bullish analysts who model revenue growing 1.7% annually over the next three years and earnings potentially reaching US$29.2 million by around 2028, yet the provided data also state that forecasts do not show profitability within the next three years, which is an important caveat for that optimistic path.

Bulls argue that a 0.3x P/S and the long term margin story could eventually meet in the middle, and if you want to see how that argument is built out in detail you might find the dedicated bull case breakdown useful. 🐂 Health Catalyst Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Health Catalyst on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of concern and optimism around Health Catalyst feels finely balanced, take a closer look at the numbers yourself and move quickly to frame your own stance. You can start with 1 key reward and 1 important warning sign.

See What Else Is Out There

With trailing twelve month net losses of US$177.9 million on US$311.1 million of revenue and no forecasted profitability within three years, risk remains elevated.

If that level of uncertainty makes you want steadier ground, this is a good moment to check out 68 resilient stocks with low risk scores and quickly focus on businesses with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com